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Abstract
Background: Fresh frozen plasma (FFP) is the accepted standard treatment for clotting factor replacement in
bleeding patients during or immediately after cardiac surgery. In the United Kingdom prothrombin complex
concentrate (PCC) is not licensed in this setting, although it is being used in Europe because it has a higher
concentration of clotting factor levels, and it can be administered rapidly and in small volume, resulting in less
volume overload during cardiac surgery.
Methods: PROPHESY is a pragmatic, single-centre, open-label, randomised, controlled pilot trial that will assess
whether it is feasible to perform a large trial in the future that will compare PCC versus FFP in patients who
are bleeding (not on warfarin) and who require blood transfusion. Over a 15-month period, 50 patients will be
randomised to PCC versus FFP if they develop active bleeding within 24 h of cardiac surgery and for whom
the clinician has decided to administer FFP for treatment of bleeding. Standard laboratory and point-of-care
assessments will be performed as per routine practice, and additional research blood samples will be taken at
three time points to assess haemostasis. Subjects will be assessed daily up to hospital discharge or 30 days or
death (whichever occurs first) and will be seen in follow-up for 90 days after surgery to assess for thromboembolic
complications and hospital re-admission since discharge. Quality-of-life assessment will be performed pre-surgery
and at 90 days post-surgery. We will also perform qualitative research with clinical experts and patients to explore
the understanding of and experience with the interventions, as well as adherence to study procedures and
protocol.
Discussion: There have been no randomised controlled trials that have compared the safety and efficacy of FFP
versus PCC in cardiac surgery patients who are bleeding. This pilot study will assess if individual components of a
large trial are deliverable to assess the safety and efficacy of the two blood products in the future.
Trial registration: EudraCT, 2018-003041-41; ClinicalTrials.gov, NCT03715348. Registered on 29 July 2018.
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Background
Approximately 30,000 cardiac procedures are per-
formed each year in the United Kingdom, and it is
estimated that approximately 10% of all blood sup-
plied by the National Blood Service is used during
these procedures. Bleeding after cardiac surgery that
requires blood transfusion is associated with signifi-
cant morbidity and mortality, resulting in substantial
costs to healthcare systems [1]. The national com-
parative audit in the United Kingdom in 2011, which
incorporated data from 66% of all UK cardiac cen-
tres, showed that the overall blood transfusion rate
was high across all procedures, with fresh frozen
plasma (FFP) being administered in over 20% of pa-
tients undergoing valve replacement or repair surger-
ies and in 30% of patients undergoing combined
coronary artery bypass graft + valve repair/replace-
ment surgeries [2].
FFP is the accepted standard treatment for re-
placement of clotting factors in bleeding patients
undergoing cardiac surgery; yet, in a recent
Cochrane review only 1 study out of 14 trials (n =
738 participants) identified has evaluated the effi-
cacy of FFP in bleeding patients, and this was
underpowered to determine outcomes in mortality
[3]. Taking into consideration that blood transfusion
is not without risks, other haemostatic agents, such
as prothrombin complex concentrate (PCC), are be-
ing explored by clinicians for management of bleed-
ing, including in the peri-operative phase for
patients undergoing cardiac surgery. Potential ad-
vantages of PCC over FFP include increased concen-
tration of clotting factors leading to faster and more
sustained reversal of coagulopathy, improved ease
and speed of administration, reduced fluid volume
(20–40 ml compared with up to 1000 ml with FFP),
and reduced incidence of immunomodulatory side
effects.
However, to date there have been no randomised
controlled trials (RCT) that have compared the clin-
ical efficacy and safety of PCC versus FFP in bleed-
ing cardiac surgery patients who are not taking
vitamin K antagonists (e.g., warfarin), and this was
highlighted in a recent systematic review [4]. Several
observational studies have demonstrated that PCC is
safe in this setting and that its administration is as-
sociated with reduced blood transfusion require-
ments, albeit with no difference in other outcomes
[5, 6]. However, clinical equipoise and the lack of
high-quality evidence means that an RCT is required
to determine how PCC compares with FFP. Prior to
such a trial, a pilot study is required to determine if
a large-scale RCT is possible, and this is the hypoth-
esis of our single-centre RCT.
Methods
Study design
The study design is a single-centre (Barts Health NHS
Trust), open-label, non-blinded, pragmatic, pilot RCT
(see Fig. 1 for study flowchart).
Aim and objectives
The aim of this study is to determine if it is feasible to
deliver a large trial in the future that will compare FFP
versus PCC in cardiac surgery patients who are bleeding
within 24 h of surgery.
Primary objective
The primary objective is to evaluate the recruitment
rate, defined as the proportion of subjects who consent
to the study (of all those eligible) and receive the
intervention.
Secondary objectives
The following are secondary objectives of this study:
1. Assess the delivery of different components of the
trial, protocol compliance and violation, and the
ability to collect outcome data
2. Compare the impact of FFP and PCC on the
haemostatic capacity of bleeding patients through
the use of standard clotting tests and other global
clotting tests
3. Obtain input from patients, members of the public
and healthcare professionals on the design/running
of the large trial, as well as identify the most
important primary/secondary outcomes for the
larger trial
Primary outcome
The primary outcome will be the proportion of partici-
pants who receive the intervention within 24 h of sur-
gery, out of all eligible participants.
Secondary endpoints
The secondary endpoints of the study are as follows:
 Time to administration of study drug (PCC) or
control (FFP) to patient, defined as time in minutes
from telephoning laboratory to first administration
to patient
 Proportion of patients for whom clinical outcome
data were collected up to 90 days, or death,
whichever occur first
 Proportion of patients who consent and are
randomised within 24 h of surgery
 Proportion of patients who consent and are not
randomised within 24 h of surgery
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 Proportion of patients for whom timing of
administration and completion of intervention(s) are
documented
 Proportion of patients in whom there is protocol
adherence and protocol violation
 Proportion of patients who do not consent to
intervention but agree to consenting of their de-
identified data for up to 24 h after surgery
 Obtain data on event rates in both groups to help
estimate the sample size for the large trial. Event
Fig. 1 Study flowchart
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rates will be assessed at 24 h and 7, 14, 21 and 30
days, or upon discharge or death, whichever is first.
Clinical outcomes assessed at these time points
include those described under ‘Study assessment’,
such as total days in intensive care unit, any organ
failure, thrombosis, acute transfusion reaction,
infections, duration of organ support and mortality.
Study population
A total of 50 patients will be randomised over a 15-
month period, with follow-up at 90 days or death,
whichever occurs first. Consent will be obtained
from all patients prior to participation in the trial.
Inclusion criteria
The study will include adult patients (aged > 18 years)
who are able to give consent and undergoing elective or
non-elective cardiac surgery, excluding procedures listed
below under ‘Exclusion criteria’.
Exclusion criteria
Exclusion criteria are inability to consent; patients
refusing blood transfusion for any reason; first time
isolated coronary artery bypass graft; first time iso-
lated aortic valve replacement (excluding active
endocarditis); thoraco-abdominal surgeries; minor
surgeries that do not involve cardiopulmonary by-
pass; use of warfarin within 4 days; use of direct oral
anticoagulants (i.e., dabigatran, rivaroxaban, apixaban
or edoxaban) within 48 h or 72 h, depending on esti-
mated glomerular filtration rate; inherited bleeding
disorder; pregnancy; known or suspected allergy to
FFP, octaplasLG (Octapharma, Lachen, Switzerland)
or PCC; known or suspected allergy to heparin, so-
dium citrate dihydrate, sodium dihydrogen phosphate
dihydrate and glycine; history of heparin-induced
thrombocytopenia; immunoglobulin A (IgA) defi-
ciency with known antibodies against IgA; docu-
mented venous thromboembolism in the last 3
months; documented antiphospholipid syndrome; se-
vere protein S deficiency; and participation in an-
other clinical trial where the patient has received an
investigational medicinal product in the last 3
months.
For women of childbearing age (< 50 years old) a urine
pregnancy test will be performed for eligibility purposes.
There will be no other study-specific screening
procedures.
To determine the bleeding rate, routine clinical
data will also be collected for up to 24 h for (1) eli-
gible participants who have consented to take part in
the study but are not randomised because they did
not develop bleeding and (2) eligible participants
who have not consented to take part in the main
study but have consented to the collection of de-
identified routine data.
Randomisation process
The pragmatic nature of the study means that the
decision whether to administer the intervention will
be based on clinicians’ judgement, so that when a
patient is actively bleeding within 24 h of surgery
and a clinician has decided that FFP is needed to
treat the bleeding, the patient will be randomised by
the transfusion laboratory to either a single dose of
FFP (fresh frozen plasma or octaplasLG) or 4-factor
PCC (octaplex; Octapharma) using a web-based elec-
tronic database. Block randomisation will be used to
ensure balance of treatments. The algorithm will be
written by the study statistician using the ralloc
command in Stata software (StataCorp, College Sta-
tion, TX, USA), and a randomisation list will be pro-
duced. In the United Kingdom it is recommended
that, as a variant Creutzfeldt-Jakob disease risk re-
duction measure, individuals born after 1 January
1996 should be transfused non-UK plasma, and this
has been the practice since 1999 [7]. At the study
site, octaplasLG is the standard of care for manage-
ment of such patients who are bleeding. Doses of
intervention will be calculated according to subject
weight and as per the dosing schedules below.
Subject weight FFP or octaplasLG
≤ 60 kg 3 units
61–90 kg 4 units
> 90 kg 5 units
Subject weight octaplex (IU)
≤ 60 kg 500 (one vial)
61–90 kg 1000 (two vials)
> 90 kg 1500 (three vials)
If the subject continues to bleed after this first
single dose of study treatment, standard care for the
treatment of bleeding will continue as per hospital
protocol, and this may include having additional FFP.
However, no further PCC will be administered to
these subjects.
Study assessments
Subjects will have laboratory assessments with
standard routine care tests and thromboelastography.
Research blood samples will also be taken at three
time points (pre-intervention and 1 h and 24 h post-
intervention) to perform a more detailed analysis of
haemostatic capacity of subjects (see Table 1 in
Appendix, Additional file 1). Samples will be stored
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at − 70 °C ± 10 °C within 4 h of collection until they
have been analysed, and no longer than 3 years after
their collection. After analysis all samples will be
destroyed. Samples will also be destroyed if the par-
ticipant withdraws consent.
Clinical data that will be collected include age, sex,
ethnicity, previous medical history, drug history, type
of surgery and date/time of intervention. For those
who have received intervention, daily and weekly (24
h and 7, 14, 21 and 30 days, or upon discharge, or
death, whichever is first) assessments will be
performed for amount of blood lost through the
chest drains, blood components transfused (red
blood cells, FFP, platelets and cryoprecipitate), any
other haemostatic agents administered (such as
recombinant factor VIIa, fibrinogen concentrate),
total days in intensive care unit (level 3), high-
dependency units (level 2), any organ failure (e.g.,
acute lung injury, acute respiratory distress syn-
drome, renal failure, liver failure), thrombosis (arter-
ial and venous thrombosis), acute transfusion
reaction, infections, duration of organ support (i.e.,
ventilatory support, cardiovascular support, and renal
replacement therapy), and mortality. At 90 days or
death, whichever is first, the following data will be
collected: mortality, re-hospitalisation, thrombo-
embolic event (arterial and venous), number of days
alive and out of hospital since operation, and
quality-of-life questionnaire.
Statistics
Sample size calculation
Over a 15-month period, we expect 638 patients to
be eligible. This would allow us to estimate a consent
rate of 30% within a 95% confidence interval of ±
3.5%. Assuming that 30% of the eligible patients con-
sent, we will have a sample of 191 patients on the
basis of which to estimate the proportion of con-
sented patients who bleed and are administered FFP/
PCC. From the national and local cardiac audit data,
the rate of FFP transfusion in the eligible study pa-
tients is just over 30%, so we have estimated that
30% of consented patients will go on to develop
bleeding during surgery that requires FFP transfusion.
A sample size of 191 would allow us to estimate a
proportion of 30% within a 95% confidence interval
of ± 6.5%. On the basis of the above 30% rate, around
57 patients would be randomised within 15 months,
giving an expected final sample size of 50 patients
completing the study after allowing for 10% drop-out
or loss to follow-up. This sample would be analysed
for assessment of the secondary endpoints. No formal
interim analysis for efficacy is planned. Numbers
recruited, eligibility and consent rates will be consid-
ered by the data and safety monitoring committee
(DSMC). Safety analysis including reporting of adverse
events will be undertaken biannually for review by
the DSMC. Other interim analysis may be undertaken
at the request of the DSMC. Tables will be prepared
by the study statistician.
The primary analysis will use data from the
eligible patient population (for consent rate
estimation) and the consenting patients (for
estimation of the percentage who are randomised
and receive study treatment). The proportion of
patients who agree to collection of their de-
identified data for up to 24 h after surgery will be
obtained to analyse the population of eligible pa-
tients who do not consent to enter the main trial.
The intention-to-treat population will be used to
analyse secondary endpoints relating to the delivery
of the intervention, clinical outcome data and
haemostatic capacity of patients. Full details of the
statistical considerations are given in the study stat-
istical analysis plan.
Discussion
There has been no RCT that has compared the
clinical efficacy and safety of PCC versus FFP in
patients undergoing cardiac surgery who are bleeding
and have not been taking a vitamin K antagonist in
the peri-operative phase. Observational studies have
suggested that PCC is safe in this setting; however,
clinical equipoise and the lack of high-quality evi-
dence mean that a large RCT is required to deter-
mine how PCC compares with FFP. Prior to such a
trial, it is important to assess the feasibility of re-
cruitment and different aspects of delivering the
large trial, and this is the aim of this pragmatic,
pilot RCT.
The pragmatic nature of the study means that the
decision whether to administer the intervention will
be based on ‘real-world’ practice rather than on a
specific algorithm. One reason for choosing this
approach is that it is vital that the results produced
from the study are applicable to everyday practice in
the future. Further, a recent phase III RCT in a
cardiac surgery setting that compared fibrinogen
concentrate with placebo highlighted some of the
challenges with trials using complex algorithms to
administer intervention [8]. Difficulties in
implementing such algorithms during trials can
result in a number of shortcomings, such as low
proportion of patients being actually randomised,
high rate of non-adherence to the study protocol,
high proportion of patients being given the
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intervention when they did not fulfil the study cri-
teria, and consequently greater costs incurred.
Furthermore, the pragmatic nature of the trial
reflects real-world current practice and does not add
pre-intervention tests that could delay the issuing of
FFP or PCC in a clinical scenario that requires rapid
action. The pilot study will collect pre-intervention
clotting profile data, but these data will not be used
as entry criteria to allow the intervention to take
place. There is no current bedside test with 100%
sensitivity and specificity to identify the need for
blood products after cardiac surgery, and as such the
trial reflects real-world practice and current clinical
judgement. There is no set limit for the amount of
blood loss to define bleeding, because although this is
possible with a closed chest and chest drains in an
intensive care unit, it is not possible to define in the
operating room before chest closure when swabs and
suction are being used.
Another important aspect of this pilot trial are
the surveys with different experts across disciplines
(e.g., cardiac surgeons, anaesthetists, intensivists,
transfusion laboratory scientists) and patient and
public groups to reach a consensus on the outcome
measures for the large trial. In 2015 Benstoem and
colleagues [9] performed a systematic review of the
literature to identify the main outcomes that have
been measured in cardiac surgery intervention trials
in adults; in this review a total of 121 outcomes
were identified, which were collapsed into 36
outcome domains. Using the results of the above
review, in 2017 Benstoem and colleagues [10]
performed an international three-round eDelphi ex-
ercise to reach a consensus on core outcome sets
that should be measured and reported, at minimum,
in clinical trials of cardiac surgery. Of the 36 out-
come variables identified from the systematic re-
view, the panel reached consensus on four core
outcome sets, which were mortality, quality of life,
hospitalisation and cerebrovascular complications.
Currently in the United Kingdom a national data-
base is used to collect clinical outcomes of patients
who have undergone cardiac surgery, and of the 4
core outcome sets agreed in the Delphi consensus
[10], quality of life is the only outcome that is not
collected by the national database, and of the 36
outcome variables identified from the systematic re-
view [9], a total of 7 variables are collected in the
United Kingdom. In order to obtain patient and
public opinion about the outcome measures for the
large trial, we will conduct surveys with patients
and UK healthcare professionals, using the results
of the above Delphi survey and the outcomes mea-
sured by the national database. Further, we will also
conduct interviews with patients and clinicians who
have been involved with the study to explore un-
derstanding of, and experience with, the interven-
tion delivered to get their input on how best to
optimise recruitment of participants and how to
improve adherence of the trial protocols. All of
these efforts will allow for a more cost-effective and
informative trial in the future.
Trial status
Protocol V2.0, 27 November 2018. Start date of subject
recruitment: 1 March 2019. Project recruitment
completion date: 30 June 2020.
The study was peer-reviewed by three independent
experts as part of the BHF funding application and
underwent Barts Heart Centre independent peer re-
view. The study protocol has been reviewed by the
Barts Cardiovascular Clinical Trials Unit (CVCTU)
Scientific Committee and the Blizard Institute, Med-
icines and Healthcare products Regulatory Agency
(MHRA) and NHS research ethics committees.
CVCTU will oversee the management and conduct of
the trial and will be responsible for pharmacovigilance
and safety reporting, coordination of trial committees,
statistical analysis and reporting, and database
management and case report form (CRF) design. The
study sponsor will be responsible for trial monitoring.
When the research trial is complete, it is a sponsor
requirement that the records be kept for a further 20
years in a secure, long-term storage facility as per the
sponsor policy.
Data will be captured in REDCap, a web-based
electronic database, for all study participants, and
the database will be held on a secure server at
Queen Mary University of London (QMUL). Partici-
pants eligible for the study will be given a screening
number, and this number will be used to identify
them throughout the study duration. The screening
number will be identified on all electronic case re-
port forms (eCRFs) and study documentation (e.g.,
questionnaires, laboratory reports, enrolment and
dispensing logs). Only authorised users approved by
the chief investigator (CI) will have access to the
REDCap electronic database, and each user will be
assigned specific user roles and rights. Sponsor rep-
resentatives and CVCTU team members will have
read-only access to the data. The study research
nurse will be the primary person with delegated re-
sponsibility for data entry and CRF completion. The
transfusion laboratory team will have access to the
eCRF to complete randomisation. The CI will have
overall responsibility for data captured in the eCRF
and be able to review, lock and electronically sign
the completed eCRFs.
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Appendix
Table 1 Assessments of randomised subjects
Study Procedure Screening
pre-
operatively
Prior to
surgery
(time 0)
Prior to
randomisation –
intervention
1 h post-
study
intervention
24 h
post-
surgery
Days 7,
14, 21
Day 30
(discharge/
death)
Day 90
(discharge/
death)
Visit windows − 14 days Day 0 Day 0 Day 0 Day 1 +/− 1
day
+/− 2 days +/− 7 days
Screening - assess eligibility
(includes urine pregnancy test)
X
Informed consent X
Patient characteristics X
Assessment by surgical team X
Assessment by anaesthesiologist X
Blood testsa – FBC X X X X
Blood testsa - group and screen
samples
X X
Blood testsa – liver and renal
function tests
X X
Routine coagulation tests (PT,
aPTT and fibrinogen)a
X X X X
Additional clotting assaysb X X X
Thromboelastographic
assessmenta
X X X
Inform transfusion laboratory of
need for FFP
X
Randomisation and intervention –
PCC or octaplasLG /FFP
X
Time of intervention (start and
stop)
X
Weekly ICU assessment X X
Thromboembolic AE/SAE X X X X X
Transfusion AE/SAE X X X X
Hospital re-admission since
discharge
X
Quality of life – EQ-5D X X
90-Day survival status - end of
study form (telephone or clinic
visit)
X
Abbreviations: AE adverse events, aPTT activated partial thromboplastin time, EQ-5D EuroQol 5-dimension quality of life scale, FBC full blood count, FFP fresh frozen
plasma, ICU intensive care unit, PCC prothrombin complex concentrate, PT prothrombin time, SAE serious adverse events
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that the records be kept for a further 20 years in a secure, long-term storage
facility as per the sponsor policy.
Trial committees have been established to oversee and monitor the trial
conduct and patient safety.
The trial steering committee (TSC) is chaired by an independent cardiac
surgeon (Justin Nowell, St. George’s Hospital), with three other independent
members (Dr Nick Fletcher, consultant anaesthetist, St. George’s Hospital, UK;
Dr. Nicola Curry, consultant haematologist, Oxford University Hospital NHS
Trust, UK; and Steve Stevenson, lay representative). The TSC provides overall
supervision of the trial and ensures that it is being conducted according to
the protocol, good clinical practice and relevant regulations. This committee
also monitors trial progress in relation to recruitment, data capture and
completeness, protocol deviations, and subject withdrawals. The committee
meets every 6 months.
The data and safety monitoring committee (DSMC) is chaired by an
independent haematologist (Prof Mike Laffan, Imperial College London, UK)
with an independent anaesthetist (Dr Paul Diprose, University of
Southampton, UK) and statistician (Dr Phil Edwards, London School of
Hygiene and Tropical Medicine, UK). The DSMC is responsible for reviewing
the trial data throughout the study and assessing whether there are any
safety issues that need to be brought to the attention of the TSC or if there
are any ethical reasons why the trial should not continue.
Study data are collected and managed using REDCap (research electronic
data capture) tools [11] hosted at Barts Cancer Centre, QMUL. REDCap is a
secure, web-based application designed to support data capture for research
studies, providing (1) an intuitive interface for validated data entry, (2) audit
trails for tracking data manipulation and export procedures, (3) automated
export procedures for seamless data downloads to common statistical pack-
ages, and (4) procedures for importing data from external sources [11].
Internal audits will be performed by the sponsor throughout the study, and
MHRA, which is independent from the investigators, and the sponsor may
audit the study.
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